Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 01, 2023

SELL
$118.43 - $186.05 $96,994 - $152,374
-819 Reduced 44.93%
1,004 $150,000
Q3 2022

Nov 09, 2022

BUY
$127.65 - $183.11 $8,041 - $11,535
63 Added 3.58%
1,823 $246,000
Q2 2022

Aug 09, 2022

BUY
$123.25 - $186.24 $31,059 - $46,932
252 Added 16.71%
1,760 $262,000
Q1 2022

May 13, 2022

BUY
$126.25 - $231.85 $135,340 - $248,543
1,072 Added 245.87%
1,508 $257,000
Q4 2021

Feb 03, 2022

BUY
$216.64 - $362.52 $86,222 - $144,282
398 Added 1047.37%
436 $112,000
Q3 2021

Nov 04, 2021

BUY
$205.93 - $447.23 $7,825 - $16,994
38 New
38 $10,000

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $28.5B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Anfield Capital Management, LLC Portfolio

Follow Anfield Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Anfield Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Anfield Capital Management, LLC with notifications on news.